The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent

Annals of Surgery

Volumn 247, Issue 2, 2008, Pages 365-371

  Mariette, Christophe ^a,b   Piessen, Guillaume ^a,b   Briez, Nicolas ^a   Triboulet, Jean Pierre ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 38549126599     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31815aaadf     Document Type: Article

References (32)

1. Mariette C, Triboulet JP. Is preoperative chemoradiation effective in treatment of oesophageal carcinoma? Lancet Oncol. 2005;6:635-637.
2. Mariette C, Piessen G, Lamblin A, et al. Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma. Br J Surg. 2006;93:1077-1083.
3. FFCD, EORTC, Mariette C, Triboulet JP, Seitz JF (Study Coordinators). Protocol FFCD 9901 - EORTC 22001/40001. Randomized study of preoperative radiochemotherapy versus surgery alone in thoracic esophageal cancer deemed to be resectable. FFCD and EORTC, 2002. Available at http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=257600&version=patient&protocolsearchid= 1096015.
4. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545-553.
5. Mariette C, Balon JM, Piessen G, et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003;97:1616 -1623.
6. Siewert JR, Stein HJ, Feith M, et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234:360-367.
7. Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg. 2001;234:581-587.
8. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662-1669.
9. Eloubeidi MA, Desmond R, Arguedas MR, et al. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002;95:1434-1443.
10. Roder JD, Busch R, Stein HJ, et al. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg. 1994;81:410-413.
11. Tachibana M, Dhar DK, Kinugasa S, et al. Esophageal cancer with distant lymph node metastasis: prognostic significance of metastatic lymph node ratio. J Clin Gastroenterol. 2000;31:318-322.
12. Sobon LH, Wittekind C, eds. UICC TNM Classification of Malignant Tumors. 6th ed. New York: Wiley; 2002.
13. Japanese Research Society for Esophageal Diseases. Guidelines for the clinical and pathologic studies for carcinoma of the esophagus. Jpn J Surg. 1976;6:79-86.
14. Hagen JA, DeMeester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520-530.
15. Ellis FH, Watkins E, Krasna MJ, et al. Staging of carcinoma of the esophagus and cardia: a comparison of different staging criteria. J Surg Oncol. 1993;52:231-235.
16. Rice TW, Blackstone EH, Rybicki LA, et al. Refining esophageal cancer staging. J Thorac Cardiovasc Surg. 2003;125:1103-1113.
17. DeMeester TR. Esophageal carcinoma: current controversies. Semin Surg Oncol. 1997;13:217-233.
18. Fujita H, Kakegawa T, Yamana H, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg. 1995;222:654-662.
19. Mariette C, Triboulet JP. Should resectable esophageal cancer be resected? Ann Surg Oncol. 2006;13:447-449.
20. Gebski V, Burmeister B, Smithers BM, et al. Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-234.
21. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol. 2003;21:4592-4596.
22. Mariette C, Balon JM, Maunoury V, et al. Value of endoscopic ultrasonography as a predictor of long-term survival in oesophageal carcinoma. Br J Surg. 2003;90:1367-1372.
23. D'Journo XB, Doddoli C, Michelet P, et al. Transthoracic esophagectomy for adenocarcinoma of the oesophagus: standard versus extended two-field mediastinal lymphadenectomy? Eur J Cardiothorac Surg. 2005;27:697-704.
24. van Sandick JW, Gisbertz SS, ten Berge IJ, et al. Immune responses and prediction of major infection in patients undergoing transhiatal or transthoracic esophagectomy for cancer. Ann Surg. 2003;237:35-43.
25. Skinner DB. En bloc resection for neoplasms of the esophagus and cardia. J Thorac Cardiovasc Surg. 1983;85:59-71.
26. Nigro JJ, DeMeester SR, Hagen JA, et al. Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. J Thorac Cardiovasc Surg. 1999;117:960-968.
27. Korst RJ, Rusch VW, Venkatraman E, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg. 1998;115:660-669.
28. Rusch VW. Should the esophageal cancer staging system be revised? J Thorac Cardiovasc Surg. 2003;125:992-993.
29. Dhar DK, Tachibana M, Kinukawa N, et al. The prognostic significance of lymph node size in patients with squamous esophageal cancer. Ann Surg Oncol. 2002;9:1010-1016.
30. Kodera Y, Yamamura Y, Shimizu Y, et al. The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. J Am Coll Surg. 1998;187:597-603.
31. Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer. 2005;103:2006-2014.
32. Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2005;23:8706-8712.